A phase 3, double-blind, randomized, multisite trial of the efficacy, safety, and tolerability of the fixed combination torcetrapib/atorvastatin administered orally, once daily for 12 months, compared to atorvastatin alone, titrated based on NCEP [National Cholesterol Education Program] ATP [Adult Treatment Panel]-III LDL-C [low density lipoprotein cholesterol] goals in subjects with Fredrickson types IIa and IIb dyslipidemias

Trial Profile

A phase 3, double-blind, randomized, multisite trial of the efficacy, safety, and tolerability of the fixed combination torcetrapib/atorvastatin administered orally, once daily for 12 months, compared to atorvastatin alone, titrated based on NCEP [National Cholesterol Education Program] ATP [Adult Treatment Panel]-III LDL-C [low density lipoprotein cholesterol] goals in subjects with Fredrickson types IIa and IIb dyslipidemias

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2006

At a glance

  • Drugs Atorvastatin; Torcetrapib/atorvastatin
  • Indications Lipid metabolism disorders
  • Focus Biomarker; Registrational; Therapeutic Use
  • Most Recent Events

    • 05 Dec 2006 Status change
    • 25 Sep 2006 Status change
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top